Abstract
Cardiovascular diseases, including myocardial infarction and heart failure, are the main causes of death worldwide. Classical pharmacological treatment may halt, but cannot reverse the underlying disease process. Cellular cardiomyoplasty has the potential to reconstruct myocardium in situ; yet, it is hampered by poor cell survival, engraftment, and differentiation. Tissue engineering has emerged as an alternative cell-based approach, aiming at partial or full replacement of damaged organs with in vitro generated tissue equivalents. However, limited availability of therapeutic cardiomyocytes poses a major challenge on cell-based and in particular tissue engineering-based therapies. Rapidly evolving stem cell technologies, enabling mass cultures may overcome this limitation. Translating available experimental concepts into clinical reality will be the ultimate challenge. This review discusses potentially therapeutic cells for cardiac repair, current stem cell-based myocardial tissue engineering strategies, and the requirements for a translation of myocardial tissue engineering into clinical practice.
Keywords: Myocardial infarction, heart failure, cardiomyoplasty, tissue engineering, myocardial regeneration, stem cells
Current Pharmaceutical Biotechnology
Title:Myocardial Tissue Engineering and Heart Muscle Repair
Volume: 14 Issue: 1
Author(s): Bijoy Chandapillai Karikkineth and Wolfram-Hubertus Zimmermann
Affiliation:
Keywords: Myocardial infarction, heart failure, cardiomyoplasty, tissue engineering, myocardial regeneration, stem cells
Abstract: Cardiovascular diseases, including myocardial infarction and heart failure, are the main causes of death worldwide. Classical pharmacological treatment may halt, but cannot reverse the underlying disease process. Cellular cardiomyoplasty has the potential to reconstruct myocardium in situ; yet, it is hampered by poor cell survival, engraftment, and differentiation. Tissue engineering has emerged as an alternative cell-based approach, aiming at partial or full replacement of damaged organs with in vitro generated tissue equivalents. However, limited availability of therapeutic cardiomyocytes poses a major challenge on cell-based and in particular tissue engineering-based therapies. Rapidly evolving stem cell technologies, enabling mass cultures may overcome this limitation. Translating available experimental concepts into clinical reality will be the ultimate challenge. This review discusses potentially therapeutic cells for cardiac repair, current stem cell-based myocardial tissue engineering strategies, and the requirements for a translation of myocardial tissue engineering into clinical practice.
Export Options
About this article
Cite this article as:
Chandapillai Karikkineth Bijoy and Zimmermann Wolfram-Hubertus, Myocardial Tissue Engineering and Heart Muscle Repair, Current Pharmaceutical Biotechnology 2013; 14 (1) . https://dx.doi.org/10.2174/1389201011314010003
DOI https://dx.doi.org/10.2174/1389201011314010003 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Saffron-Based Crocin Prevents Early Lesions of Liver Cancer: In vivo, In vitro and Network Analyses
Recent Patents on Anti-Cancer Drug Discovery The Biology and Therapeutic Potential of the DDAH/ADMA Pathway
Current Pharmaceutical Design Targeting Aldose Reductase for the Treatment of Cancer
Current Cancer Drug Targets Editorial [Hot Topic:Cell Metabolism as Therapeutic Target in Human Disease (Executive Guest Editors: Walter Malorni and Rosa Vona)]
Current Pharmaceutical Design Update on COX-2 Selective Inhibitors: Chemical Classification, Side Effects and their Use in Cancers and Neuronal Diseases
Current Topics in Medicinal Chemistry Women’s Ginseng (Angelica sinensis): An Ethnopharmacological Dossier
Current Traditional Medicine A Mitochondrial Approach to Cardiovascular Risk and Disease
Current Pharmaceutical Design Potential Adverse Effects Associated with Inhibition of p38α/β MAP Kinases
Current Topics in Medicinal Chemistry A Review on Electrocardiographic Changes in Diabetic Patients
Current Diabetes Reviews MicroRNAs as Early Biomarkers in Obesity and Related Metabolic and Cardiovascular Diseases
Current Pharmaceutical Design Tissue Factor and Hypertension
Current Hypertension Reviews Role of Angiotensin-1-Receptor Blockers In Cardiorenal Disease
Current Drug Therapy Targeted Drug Delivery for Breast Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery A Molecular Bridge: Connecting Type 2 Diabetes and Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Using Extracellular Matrix-Derived Peptides to Alter the Microenvironment for Myocardial Repair
Current Vascular Pharmacology Therapeutic Utilisations of Vasopressin and Oxytocin in Mood Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Early Growth Response-1 (EGR-1) – A Key player in Myocardial Cell Injury
Cardiovascular & Hematological Agents in Medicinal Chemistry Contextualizing the Genes Altered in Bladder Neoplasms in Pediatric and Teen Patients Allows Identifying Two Main Classes of Biological Processes Involved and New Potential Therapeutic Targets
Current Genomics Zinc and Copper Homeostasis in Head and Neck Cancer: Review and Meta-Analysis
Current Medicinal Chemistry Anti-HER2 Therapy in Elderly Breast Cancer Patients
Reviews on Recent Clinical Trials